Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation

Major Program

Phase 0 I II Cancer Prevention Clinical Trials Program

Research Group

Gastrointestinal and Other Cancers

Status

Active, not recruiting

NCT ID

NCT02521285

This randomized phase II trial studies the safety of and how well aspirin works in preventing Barrett's esophagus from returning after it has been successfully eliminated by radiofrequency ablation. Studying samples of tissue from patients with Barrett's esophagus for the levels of a specific protein that is linked to developing Barrett's esophagus may help doctors learn whether aspirin can prevent it from returning after it has been successfully treated.

Intervention

Aspirin, Laboratory Biomarker Analysis, Placebo Administration, Questionnaire Administration

Condition

Barrett Esophagus, Esophageal Adenocarcinoma

Investigators

Robert S Bresalier

See list of participating sites